Research Paper Volume 12, Issue 13 pp 13255—13280

Figure 8. circMBOAT2 is associated with PCa progression and responds to mTOR inhibitor treatment. (A) Image of the xenograft subcutaneous models of PC-3 cells stably transfected with vector or circMBOAT2 plasmid, treated with rapamycin or PBS. (B, C) Tumor volumes and weights of subcutaneous xenograft tumors. (D) qRT-PCR analysis of circMBOAT2 expression in a cohort of 50 PCa patient tissues paired with their respective NATs. (E, F) The Kaplan-Meier curves for DFS of PCa patients in cohort 1 and cohort2. Median circMBOAT2 expression levels were used as the cutoff value for patient stratification. (G) Proposed model of circMBOAT2-mediated PI3K/Akt activation in PCa tumorigenesis and metastasis. Data are displayed as mean ± SD. *p < 0.05; **p < 0.01.